Skip to main content
. Author manuscript; available in PMC: 2015 Jan 21.
Published in final edited form as: ISRN Minim Invasive Surg. 2012;2012:942364. doi: 10.5402/2012/942364

Figure 5.

Figure 5

The Kaplan-Meier estimate of overall survival (OS) in the 59 study eligible patients. The dashed lines represent the 95% confidence interval (CI) about each successive estimate of the survival rate. The median OS was 24.8 months (95% CI, 18.3–36.5 months) for patients who received chemotargeted therapy following their first MCA procedure, and 23.5 months (95% CI, 14.2–34.1 months) for patients who only received best supportive care following first MCA. The 2- and 3-year OS rate for the chemo-targeted group was 52% (95% CI, 29%–75%) and 33% (95% CI, 9%–56%), respectively. For the BSC only group, the 2- and 3-year OS rate was 44% (95% CI, 25%–63%) and 22% (95% CI, 3%–41%), respectively.